Clinical Trial Update: A Study of TAK-625 for the Treatment of Alagille Syndrome (ALGS) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating TAK-625 for Alagille Syndrome has completed, with results posted in October 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alagille Syndrome

Drugs mentioned

• TAK-625

Snippet

Sponsor: Takeda | Conditions: Alagille Syndrome (ALGS) | Phase 3 | Status: COMPLETED | Results posted: 2024-10-15